Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.34 |
| ▸ | SLC34A1 | Q06495 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25686878 | 1.00 | CFTR (0.34) | CFTRSLC34A1CYP11B1CYP11B2ADORA2A | |
| SCHEMBL30007480 | 1.00 | CFTR (0.34) | CFTRSLC34A1CYP11B1CYP11B2ADORA2A | |
| SCHEMBL23958695 | 1.00 | CFTR (0.34) | CFTRSLC34A1CYP11B1CYP11B2ADORA2A | |
| SCHEMBL23958729 | 0.89 | CFTR (0.35) | CFTRTNIKTGFBR1 | |
| SCHEMBL23958689 | 0.89 | CFTR (0.35) | CFTRTNIKTGFBR1 | |
| SCHEMBL30006775 | 0.89 | CFTR (0.35) | CFTRTNIKTGFBR1 | |
| SCHEMBL23958643 | 0.89 | CFTR (0.35) | CFTRTNIKTGFBR1 | |
| SCHEMBL25275870 | 0.83 | CFTR (0.39) | CFTRSLC34A1 | |
| SCHEMBL25686876 | 0.80 | CFTR (0.38) | CFTR | |
| SCHEMBL23958674 | 0.79 | CFTR (0.34) | CFTRTNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021214136-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | ACE2, SIRT7, ACE | CFTR 508/4885SLC34A1 2493/4885CYP11B1 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.